TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)

Carcinoma, Hepatocellular Clinical Trial

Official title:

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma：A Multicenter, Single-armed, Prospective, Observational Study (Prolong)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04560751
• Other study ID #: Prolong
• Status: Not yet recruiting
• Start date: September 30, 2020
• Est. completion date: August 31, 2022

Study information

• Verified date: September 2020
• Source: Zhejiang Cancer Hospital
• Contact: Guoliang Shao, Professor
• Phone: 13989898089
• Email: zenghuiray[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multicenter, prospective, observational study in which subjects will be treated with lenvatinib combined with TACE in un-resectable HCC patients who had not received systematic treatment or TACE treatment in the past.

Description:

Only 30% of HCC patients received radical resection. Most of the patients are in the advanced stage and can only receive palliative treatment such as TACE or systemic treatment. Lenvatinib is a multi-target receptor tyrosine kinase inhibitor (TKI), which mainly inhibits vascular endothelial growth factor(VEGF) receptor-1, 2, 3; fibroblast growth factors(FGF) receptor-1, 2, 3, 4; platelet derived growth factor receptor(PDGFR)α; RET and KIT and showed significant anti-tumor effect in REFLECT study. The purpose of this study is to explore the efficacy and safety of Lenvatinib and TACE in unresectable HCC patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: August 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Ages of = 18 and = 75 years old.

2. Clinically or histopathologically diagnosed as hepatocellular carcinoma (HCC).

3. China stage IIb-IIIb patients, not suitable for surgical resection.

4. The imaging examination within 2 weeks before interventional therapy showed that there was at least one target lesion that could be measured by CT or MRI, and the lesion was suitable for repeated and accurate measurement.

5. Child-Pugh scores =7.

6. ECOG:0-1.

7. Intended to be treated with TACE combined with lenvatinib.

8. Good organ and bone marrow function: Blood routine: WBC>4.0×109/L?Hb>80g/L, PLT>75×109/L, NEUT>1.5×10?/L. Blood coagulation function: International normalized ratio (INR)<1.2. Hepatic function: serum albumin (ALB)>3.5 g/dl, total bilirubin (TBIL) <1.5 × normal upper limit (ULN) (Eliminate biliary obstruction), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 3 × ULN. Renal dysfunction:serum creatinine (SCR) <1.5× ULN.

9. Agreed to join the clinical trial and sign the informed consent form.

Exclusion Criteria:

1. Hepatobiliary cell carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma.

2. With invasion of the main portal vein or vena cava.

3. Received interventional therapy such as TACE within 2 years.

4. Received systematic treatment in the past.

5. Uncontrollable ascites, hepatic encephalopathy or esophagogastric variceal bleeding.

6. Patients with hypertension who cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure > 140mmHg, or diastolic blood pressure > 90 mmHg).

7. Suffering from grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmia or myocardial ischemia or myocardial infarction (The QTc interval = 450ms, QTc interval is calculated by Fridericia formula).

8. There is a history of gastrointestinal bleeding or a clear tendency of gastrointestinal bleeding in the past 3 months, such as esophageal varices at risk of bleeding, local active ulcer lesions, fecal occult blood = (+).

9. Pregnant or lactating women. A fertile patient who is unwilling or unable to use effective contraception.

10. Patients with HIV infection.

11. Suspected allergy to research drugs.

12. Other situations which the researchers considered ineligible for participating in the trial.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Drug:
• Lenvatinib
Lenvatinib capsules will be administered orally, once daily (for patients <60kg, lenvatinib 8mg po; for patients =60kg, lenvatinib 12mg po)

Procedure:
• TACE
TACE will be performed as needed.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Cancer Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate(ORR)	The percentage of patients who have best overall response of complete response (CR) or partial response (PR) according to mRECIST.	up to 12 months
Secondary	Intrahepatic ORR and Extrahepatic ORR	The percentage of patients who have best overall response of complete response (CR) or partial response (PR) according to mRECIST intrahepatic or extrahepatic, respectively.	up to 12 months
Secondary	Progression-free survival (PFS)	The time from the beginning of treatment of TACE to the time of tumor progression or death from any cause (according to mRECIST standard)	up to 12 months
Secondary	Alpha-fetoprotein (AFP) response rate	A decrease in AFP of more than 20% in AFP+ patients treated with lenvatinib is defined as an AFP response.AFP response rate defined as the percentage of AFP response patients in all AFP positive patients.	up to 12 months
Secondary	Time to progression(TTP)	The time from the beginning of treatment of TACE to the time of tumor progression. (according to mRECIST standard)	up to 12 months
Secondary	Adverse events(AEs)	AEs(adverse events) evaluated by the CTC-AE 5.0	up to 18 months